Trials / Completed
CompletedNCT01249547
Nasopharyngeal Carcinoma (NPC) Axitinib
Phase 2 Study of Axitinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Chinese University of Hong Kong · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, single arm, phase 2 clinical trial evaluating the activity and safety of single-agent axitinib in recurrent or metastatic NPC patients who failed at least one line of platinum based chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | axitinib | starting dose of 5 mg twice daily for 4 consecutive weeks without interruption. |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2010-11-30
- Last updated
- 2017-04-25
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT01249547. Inclusion in this directory is not an endorsement.